Recent findings published by Pharmacy Times highlight Elinzanetant as a promising non-hormonal treatment option for menopausal vasomotor symptoms. Elinzanetant distinguishes itself by offering a safe and well-tolerated alternative for those seeking relief from symptoms such as hot flashes and night sweats, which often accompany menopause. This new therapy stands out particularly because it avoids the hormonal approach traditionally used, thereby being suitable for individuals unable to use hormone replacement therapies. Clinical trials have demonstrated Elinzanetant’s effectiveness and minimal side effects, positioning it ideally for broad usage. As more women seek non-hormonal solutions for menopausal management, Elinzanetant’s emergence could significantly impact how symptoms are treated globally. This advancement marks a crucial development in women’s health, offering hope to millions experiencing menopausal discomfort.
Pharmacy TimesNew data shows Britain’s night-time economy shrinks by 350 venues in six months
October 19, 2026
New data reveals a significant decline in Britain’s night-time economy, with 350 venues closing within just six months. This downward trend highlights the ongoing challenges